Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 5, 2005, Pages 389-395

  Maalej, Nabil ^a   Osman, Hashim E ^a   Shanmuganayagam, Dhanansayan ^a   Shebuski, Ronald J ^b   Folts, John D ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CarePoint Diagnostics Inc   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

Cyclooxygenase; Platelet aggregation; Prostanoid endoperoxide; Thrombosis; Thromboxane receptor antagonist

Indexed keywords

3 [6 [[(4 CHLOROPHENYL)SULFONYL]AMINO] 2 METHYL 5,6,7,8 TETRAHYDRO 1 NAPHTHALENYL]PROPIONIC ACID; ADRENALIN; ANTITHROMBOCYTIC AGENT; COLLAGEN; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; S 18886; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; BLEEDING TIME; BLOOD PH; BLOOD PRESSURE MEASUREMENT; CARBON DIOXIDE TENSION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; DISEASE MODEL; DOG; DRUG POTENCY; DRUG STRUCTURE; ENDOTHELIUM LESION; FEMALE; HEART RATE; HEMATOCRIT; MALE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION;

ANIMALS; CORONARY STENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MOLECULAR STRUCTURE; NAPHTHALENES; PLATELET AGGREGATION; PROPIONIC ACIDS; RECEPTORS, THROMBOXANE; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; REGIONAL BLOOD FLOW; THROMBOSIS; TIME FACTORS;

EID: 18244394040     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000157439.49612.83     Document Type: Article

References (31)

1. Baigent C, Sudlow C, Collins R, et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation. 1990;82:1147-1159.
3. Wilson JM, Ferguson JJ 3rd. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin Cardiol. 1999;22:687-698.
4. Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. Hypertens Res. 1995;18:87-98.
5. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994-2998.
6. Pratico D, Cheng Y, FitzGerald GA. TP or not TP: primary mediators in a close runoff? Arterioscler Thromb Vasc Biol. 2000;20:1695-1698.
7. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:1724-1728.
8. Folts JD, Rowe GG. Cyclical reductions in coronary blood-flow in coronary arteries with fixed partial obstruction and their inhibition with aspirin. FASEB J. 1974;33:413.
9. Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 1976;54:365-370.
10. Sherry S. Aspirin and antiplatelet drugs: The clinical approach. CVR&R. 1984;5:1208-1219.
11. Folts JD, Rowe GG. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res. 1988;50:507-516.
12. Simonet S, Descombes JJ, Vallez MO, et al. S 18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig. Adv Exp Med Biol. 1997;433:173-176.
13. Verbeuren TJ, Simonet S, Descombes JJ, et al. Pharmacology of S 18886, a new potent, long acting, orally active TP-receptor antagonist. Fundam Clin Pharmacot. 1999;13:277.
14. 2 receptor antagonist. J Thromb Haemost. 2004;2:492-498.
15. 2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003;41:1198-1204.
16. Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J. 1990;4:3087-3098.
17. Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-756.
18. Folts JD, Detmer DE, Nadler MS. Possible platelet thrombi formation in dog and human femoral arteries. Tex Heart Inst J. 1982;9:19-26.
19. Eichhorn EJ, Grayburn PA, Willard JE, et al. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol. 1991;17:43-52.
20. O'Rourke ST, Folts JD, Albrecht RM. Inhibition of canine platelet aggregation by barbiturates. J Lab Clin Med. 1986;108:206-212.
21. Folts JD, Levine RL. Effects of barbiturate anesthesia on in vivo platelet thrombus formation and regional myocardial functions. FASEB J. 1984;43:420.
22. Shanmuganayagam D, Folts J. Effect of polyphenolic flavonoid compounds on platelets. Methods Enzymol. 2001;335:369-380.
23. Folts JD. Drugs for the prevention of coronary thrombosis: From an animal model to clinical trials. Cardiovasc Drugs Ther. 1995;9:31-43.
24. Folts JD. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83:IV3-IV14.
25. 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987;76:952-959.
26. Roux SP, Sakariassen KS, Turitto VT, et al. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models. Arterioscler Thromb. 1991;11:1182-1191.
27. Coller BS. Inhibitors of the platelet glycoprotein IIb-IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Artery Dis. 1992;3:1016-1029.
28. Samama CM, Bonnin P, Bonneau M, et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. J Thromb Haemost. 1992;68:500-505.
29. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002;300:729-735.
30. 2? Circulation. 2002;105:1620-1622.
31. 2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Circ Res. 1991;69:313-324.